2022
Longitudinal alterations in mRNA expression of the BDNF neurotrophin signaling cascade in blood correlate with changes in depression scores in patients undergoing electroconvulsive therapy
Schurgers G, Walter S, Pishva E, Guloksuz S, Peerbooms O, Incio L, Arts B, Kenis G, Rutten B. Longitudinal alterations in mRNA expression of the BDNF neurotrophin signaling cascade in blood correlate with changes in depression scores in patients undergoing electroconvulsive therapy. European Neuropsychopharmacology 2022, 63: 60-70. PMID: 36067540, DOI: 10.1016/j.euroneuro.2022.07.183.Peer-Reviewed Original ResearchConceptsBrain-derived neurotrophic factorBDNF/TrkBExpression of BDNFSerum BDNF protein levelsBDNF protein levelsElectroconvulsive therapyDepression scoresMRNA expressionPeripheral bloodTreatment-resistant depressed patientsProtein levelsMechanism of actionAntidepressant effectsNeurotrophic factorDepressed patientsLongitudinal alterationsSevere depressionBlood correlatesEffective treatmentLongitudinal changesTrkBStudy periodNR3C1PatientsTherapy
2010
P03-343 - Treatment choice in psychiatry? How would European trainees treat psychosis for their patients and themselves, and what influences decision-making?
Jauhar S, Guloksuz S, Marques J, Bendix M, Lydall G, Andlauer O, Gerber S, Roventa C, Van Zanten J, De Vriendt N, Nawka A, Nwachukw I, Dobrzynska E, Mufic A, Nazaraliev A, Dumitrescu I, Mendonca L, Riese F, Group E. P03-343 - Treatment choice in psychiatry? How would European trainees treat psychosis for their patients and themselves, and what influences decision-making? European Psychiatry 2010, 25: 958. DOI: 10.1016/s0924-9338(10)70949-4.Peer-Reviewed Original ResearchFirst-line therapySide effect profileTreatment choiceClinical practicePsychiatric clinical practiceEuropean traineesCATIE trialAntipsychotic medicationAntipsychoticsResponse ratePatientsEvidence baseMinimum response ratePsychosisRecent evidenceClozapineTherapyEfficacySample sizeTraineesPsychiatryMedicationsPrescribingFactorsResponders